Bird Flu News and Research

RSS

New drug to safeguard against epidemic and pandemic flu strains

CSIRO scientists have helped to design a new drug to safeguard against epidemic and pandemic flu strains – as published in Science today.

22 Feb 2013

Cambodia, China report cases of avian influenza H5N1

"Cambodia reported on Wednesday that another four-year-old girl has contracted avian influenza H5N1, becoming the seventh person who infected the virus in 2013," Xinhua reports.

14 Feb 2013

Global response to possible H5N1 flu outbreak could affect epidemic's course

"It's been a rough flu season this winter in the United States and Europe, but it could be worse. A lot worse," science writer Carl Zimmer states in National Geographic's "Phenomena: The Loom" blog.

10 Feb 2013

FluGen's REDEE FLU vaccine protects against both H5N1 and H3N2 strains

Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU.

6 Feb 2013

Cambodian health officials strengthen avian flu awareness campaigns after 2 more deaths

"Two more children have died in Cambodia of bird flu, bringing the number of fatal cases this year to four and the number of cases overall to five," the Associated Press/Wall Street Journal reports, noting only three cases were reported in all of 2012. "WHO says bird flu, also known as avian influenza, or H5N1, has killed 360 other people worldwide since surfacing in 2003," with most cases "linked to contact with infected poultry," the news agency writes.

30 Jan 2013

Have scientists thoroughly addressed avian flu research concerns?

Noting that a nearly yearlong moratorium on H5N1 avian influenza research, put in place "because of safety and terrorism concerns," was lifted recently, a New York Times editorial states, "We wish we could be as sanguine as they are that all the earlier concerns have been dealt with."

29 Jan 2013

New research sets out alternative approach to pandemic preparedness

'Evil' scientists, deadly viruses and terrorist plots are usually the preserve of Hollywood blockbusters. But when it comes to pandemic influenza, it is the stuff of real life. As controversy about research into the H5N1 bird flu virus continues, a new paper argues for a complete overhaul of current approaches to pandemic preparedness.

29 Jan 2013

Voluntary moratorium on H5N1 research ends; fate of U.S.-funded research unknown

"Almost a year after they announced it, leading influenza researchers are ending a voluntary moratorium on certain types of controversial experiments involving the H5N1 avian influenza virus."

25 Jan 2013

Yearlong moratorium on H5N1 research soon lifted, new rules implemented, Science reports

"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.

7 Jan 2013

Voluntary moratorium on H5N1 avian flu research likely to end soon

Following the conclusion of a two-day meeting at the National Institutes of Health (NIH) this week -- meant "to gather feedback from flu researchers, others in the science community, and the public on its draft framework for funding H5N1 gain-of-function studies and to continue an international dialogue on issues related to benefits and risks of the research" -- "experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon," CIDRAP News reports.

21 Dec 2012

Meeting participants discuss HHS framework for funding H5N1 avian influenza research

CIDRAP News reports on a two-day meeting at the National Institutes of Health during which "researchers, biosecurity experts, and others" discussed the "crafting of a framework for funding H5N1 avian influenza gain-of-function studies." The meeting "is the latest chapter in an intense scientific controversy that was triggered by the publication of two recent studies involving lab-engineered H5N1 strains that showed signs of being transmissible in mammals," according to the news service.

19 Dec 2012

U.S. government's draft guidance on funding for H5N1 research receives 'mixed reception,' Science reports

"Researchers are giving a mixed reception to a draft U.S. government plan to do more stringent funding reviews of certain kinds of H5N1 avian influenza research -- and perhaps even require some studies to be kept secret," Science reports.

8 Dec 2012

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

28 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Myths about the influenza vaccine

With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.

9 Oct 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Boosting immune system can help reduce asthma attacks due to viral infections

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September.

1 Sep 2012

Climate change associated with increased risk of avian flu transmission in wild birds

Rising sea levels, melting glaciers, more intense rainstorms and more frequent heat waves are among the planetary woes that may come to mind when climate change is mentioned. Now, two University of Michigan researchers say an increased risk of avian influenza transmission in wild birds can be added to the list.

30 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012